Izenivetmab
Veterinary medication
From Wikipedia, the free encyclopedia
Izenivetmab, sold under the brand name Lenivia, is a canine monoclonal antibody medication used for the alleviation of pain associated with osteoarthritis in dogs.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | Nerve growth factor (NGF) |
| Clinical data | |
| Trade names | Lenivia |
| Other names | ZTS-00075623 |
| Routes of administration | Subcutaneous |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| Chemical and physical data | |
| Formula | C6570H10078N1750O2022S48 |
| Molar mass | 147472.00 g·mol−1 |
Izenivetmab was authorized for veterinary use in Canada in October 2025,[3] and in the European Union in November 2025.[4]
Medical uses
Izenivetmab is indicated for the alleviation of pain associated with osteoarthritis in dogs.[5]
